HEIDELBERG, GERMANY / ACCESSWIRE / July 23, 2019 / Apogenix, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, announced today that new data published in Journal for ...
Glucocorticoid-induced tumor necrosis factor receptor (GITR) and its ligand, GITRL, are involved in immune response regulation. GITR is mainly expressed in activated T cells while GITRL is primarily ...
HERA-GITRL Shows Strong Single-Agent Anti-Tumor Activity in Vitro and in Vivo and is Superior to Bivalent Clinical Benchmark Antibody Heidelberg, Germany, July 23, 2019 - Apogenix, a biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results